Identification of alemtuzumab-suitable multiple sclerosis patients in Slovakia and sequencing of post-alemtuzumab immunomodulatory treatment.

Ther Adv Neurol Disord · 2024 · PMC11528642 · PMID 39494112

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a trend towards significanceno p-value reported

However, there was a trend towards significance in ocrelizumab ( p -value 0.0523).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.